MedTrace Logo

A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy

NCT07642050 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2026-06-11

No results posted yet for this study

Summary

The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.

Conditions

Interventions

DRUG

BHV-1400

500 mg delivered subcutaneously via autoinjector

DRUG

Placebo

Matching placebo delivered subcutaneously via autoinjector

Sponsors & Collaborators

  • Biohaven Therapeutics Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-09-30
Completion
2029-10-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07642050 on ClinicalTrials.gov